Kala Pharmaceuticals (KALA) Given a $51.00 Price Target by Wedbush Analysts
Wedbush set a $51.00 target price on Kala Pharmaceuticals (NASDAQ:KALA) in a report released on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the stock.
A number of other equities research analysts have also weighed in on the stock. BidaskClub lowered shares of Kala Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, April 16th. Jefferies Financial Group assumed coverage on shares of Kala Pharmaceuticals in a report on Thursday, March 14th. They set a buy rating and a $15.00 price target for the company. Oppenheimer assumed coverage on shares of Kala Pharmaceuticals in a report on Wednesday, April 24th. They set an outperform rating and a $11.00 price target for the company. Finally, Zacks Investment Research lowered shares of Kala Pharmaceuticals from a hold rating to a strong sell rating in a report on Tuesday, March 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $19.21.
Shares of KALA traded down $0.27 during mid-day trading on Tuesday, reaching $5.96. The company’s stock had a trading volume of 1,269 shares, compared to its average volume of 165,317. The firm has a market cap of $211.07 million, a price-to-earnings ratio of -2.42 and a beta of 1.64. The company has a debt-to-equity ratio of 0.86, a quick ratio of 10.17 and a current ratio of 10.30. Kala Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $17.09.
A number of large investors have recently bought and sold shares of the stock. RA Capital Management LLC raised its holdings in Kala Pharmaceuticals by 114.7% in the 4th quarter. RA Capital Management LLC now owns 4,537,478 shares of the company’s stock worth $22,188,000 after purchasing an additional 2,424,242 shares in the last quarter. Wellington Management Group LLP raised its holdings in Kala Pharmaceuticals by 1.9% in the 1st quarter. Wellington Management Group LLP now owns 1,555,177 shares of the company’s stock worth $12,860,000 after purchasing an additional 29,534 shares in the last quarter. BlackRock Inc. raised its holdings in Kala Pharmaceuticals by 29.2% in the 4th quarter. BlackRock Inc. now owns 1,427,672 shares of the company’s stock worth $6,980,000 after purchasing an additional 322,311 shares in the last quarter. Athyrium Capital Management LP bought a new position in Kala Pharmaceuticals in the 4th quarter worth $6,520,000. Finally, Vanguard Group Inc raised its holdings in Kala Pharmaceuticals by 8.0% in the 3rd quarter. Vanguard Group Inc now owns 510,295 shares of the company’s stock worth $5,036,000 after purchasing an additional 37,738 shares in the last quarter. Institutional investors own 67.92% of the company’s stock.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.